Bristol-myers Squibb, Astrazeneca Say Fda Accepts Nda For An Onglyza Combination Drug For Type 2 Diabetes Treatment - Update
Source: RTT News
Wednesday 17th March, 2010
News ) announced Wednesday that the US Food and Drug Administration has accepted for review a New Drug Application for an investigational fixed dose combination of Onglyza and metformin HCl extended-r... ...
Read the full story at
RTT News
Email this story to a friend
Have your say on this story
